Latest News for: gaba transporter

Edit

Epilepsy Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024

GetNews 26 Sep 2024
It covers the pipeline drug profiles, including clinical and nonclinical stage products ... EPX-100 ... TRV-045 ... The KCC2 transporter is a neuron-specific chloride extruder that is critical for maintaining GABA’s inhibitory function in the mature brain.
Edit

Vigyan Yuva awardee Aravind Penmatsa: Exploring proteins in neuronal membranes

Hindustan Times 22 Aug 2024
We study transporters of neurotransmitters ... We have also looked at how antiepileptic medications target another neurotransmitter, GABA, and how these blockers specifically bind to GABA transporters.
Edit

Ace Neuroscience Releases Neurotransmitter-Related Toolbox to Accelerate Mental Illness Research

GetNews 27 Feb 2024
At Ace Neuroscience, researchers will find diverse high-quality reagents, including GABA receptors, calcium-binding proteins, glutamate receptors, neurotransmitter transporters, as well as serine ...
Edit

New scientific findings challenge the male-centric bias in autism studies

PsyPost 04 Jan 2024
GAD1 is involved in the synthesis of the inhibitory neurotransmitter GABA, NR1 is a component of NMDA receptors crucial for synaptic plasticity, VGAT is involved in GABA transport in synaptic ...
Edit

From nausea pills to hypnosis, the latest ways to beat the misery of IBS

The Daily Mail 30 Oct 2023
Lactobacillaceae bacteria, for example, make GABA (Gamma-Aminobutyric Acid), a chemical messenger that has a calming effect on the brain. The metabolites are transported to the brain by the ...
Edit

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Enid News & Eagle 04 Aug 2023
... cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies.
Edit

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Enid News & Eagle 01 Aug 2023
... cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies.
Edit

Researchers decode the structure of a crucial neural transport protein

Phys Dot Org 07 Jul 2023
GABA transporters (GATs) are the primary molecules involved in this step—they employ sodium and chloride ions to move excess GABA back into the neurons ... of GABA recognition and release into neurons.
Edit

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

Enid News & Eagle 05 May 2023
... cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies.
Edit

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of ...

Enid News & Eagle 01 May 2023
(NASDAQ ... and founder of Graviton ... Additionally, Ovid CEO Dr ... Ovid is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies ... Dr ... .
Edit

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented ...

Enid News & Eagle 27 Apr 2023
(NASDAQ ... Ovid interest in soticlestat. ... Key findings were. ... Ovid is developing OV329, a GABA aminotransferase inhibitor, for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies ... .
Edit

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

Eagle-Tribune 13 Mar 2023
Ovid is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies.
Edit

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Tyler Morning Telegraph 07 Sep 2022
Ovid is developing OV329, a GABA aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies.
Edit

Signaling molecule may regulate proteins in wheat plants

Phys Dot Org 01 Sep 2022
Outcomes of this study indicate that picrotoxin blocks transport of negatively charged ions through the protein but allows transport of GABA and that the transport is dependent on the conformation of the protein.

Most Viewed

×